Focused On-demand Library for Prominin-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O43490

UPID:

PROM1_HUMAN

Alternative names:

Antigen AC133; Prominin-like protein 1

Alternative UPACC:

O43490; Q6SV49; Q6SV50; Q6SV51; Q6SV52; Q6SV53; Q96EN6

Background:

Prominin-1, also known as Antigen AC133 and Prominin-like protein 1, plays a crucial role in cell differentiation, proliferation, and apoptosis. It binds cholesterol in plasma membrane microdomains, influencing the organization of the apical plasma membrane in epithelial cells. During retinal development, Prominin-1 is a key regulator of disk morphogenesis and is involved in the regulation of MAPK and Akt signaling pathways. In neuroblastoma cells, it suppresses differentiation, such as neurite outgrowth, in a RET-dependent manner.

Therapeutic significance:

Prominin-1 is implicated in several retinal dystrophies, including Retinitis pigmentosa 41, Cone-rod dystrophy 12, Stargardt disease 4, and Macular dystrophy, retinal, 2. These conditions highlight the protein's critical role in visual function and its potential as a target for therapeutic strategies aimed at treating retinal diseases.